deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT01216241

Daptomycin Versus Placebo in Patients With Neutropenia and Fever

A Single Center, Double-Blind, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Daptomycin Versus Placebo in Patients With Neutropenia and Fever.

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Conditions Febrile Neutropenia
Interventions Daptomycin Saline Placebo
Updated 13 times since 2017 Last updated: Mar 4, 2014 Started: Apr 30, 2011 Primary completion: Apr 30, 2013 Completion: Apr 30, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study has shown futility and the objectives could not be reached without enrolling a very large number of subjects.

Other terminated trials from Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

See all terminations from Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Listed as NCT01216241, this PHASE3 trial focuses on Febrile Neutropenia and remains terminated or withdrawn. Sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), it has been updated 13 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~May 2018 · 9 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2020 · 29 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jan 2024 · 12 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Jan 2024 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jan 2023 — Jan 2024 [monthly]

    Terminated PHASE3

  5. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE3

▶ Show 8 earlier versions

  1. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE3

  2. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE3

  3. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE3

  4. Jun 2018 — Nov 2020 [monthly]

    Terminated PHASE3

  5. May 2018 — Jun 2018 [monthly]

    Terminated PHASE3

  6. Aug 2017 — May 2018 [monthly]

    Terminated PHASE3

  7. Feb 2017 — Aug 2017 [monthly]

    Terminated PHASE3

  8. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE3

    First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
  • University of Rochester
Data source: University of Rochester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations